Of note, compared with the first generation pan-JAK inhibitors, recent studies show that highly selective JAK1 inhibitors can also achieve satisfying therapeutic efficacy for several autoimmune diseases with lower risk of causing adverse effects (4, 5), indicating JAK1’s essential role in the development of autoimmune diseases. The gene discussed is JAK1; the disease is autoimmune disease.